Walleye Capital’s Ascendis Pharma A/S ASND Stock Holding History

Walleye Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$453K	Sell	1,700 -2,000	-54%	-$467K	﹤0.01%	2839
2026 Q1	$846K	Sell	3,700 -900	-20%	-$202K	﹤0.01%	2228
2025 Q4	$981K	Buy	4,600 +3,500	+318%	+$723K	﹤0.01%	2447
2025 Q3	$219K	Buy	1,100 +400	+57%	+$74.6K	﹤0.01%	3260
2025 Q2	$121K	Buy	+700	New	+$114K	﹤0.01%	3681
2024 Q4	–	Sell	-900	Closed	-$134K	–	4829
2024 Q3	$134K	Sell	900 -1,100	-55%	-$149K	﹤0.01%	4256
2024 Q2	$273K	Sell	2,000 -1,000	-33%	-$136K	﹤0.01%	4059
2024 Q1	$454K	Buy	3,000 +2,400	+400%	+$343K	﹤0.01%	3279
2023 Q4	$75.6K	Sell	600 -1,300	-68%	-$130K	﹤0.01%	4166
2023 Q3	$178K	Sell	1,900 -700	-27%	-$65.5K	﹤0.01%	3630
2023 Q2	$232K	Sell	2,600 -3,000	-54%	-$261K	﹤0.01%	2989
2023 Q1	$600K	Sell	5,600 -900	-14%	-$103K	0.01%	1561
2022 Q4	$794K	Buy	6,500 +3,200	+97%	+$372K	0.01%	1140
2022 Q3	$341K	Buy	+3,300	New	+$313K	0.01%	1741

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Walleye Capital's ASND Position: Q2 2026 in Review

Walleye Capital increased its Ascendis Pharma A/S (ASND) stake by 340,454% in Q2 2026, buying an estimated $29.4M and bringing the position to 126,005 shares worth $33.6M. The position accounts for 0.12% of the portfolio, ranked #118.

Walleye Capital first reported a position in ASND in Q4 2023 and has held it in 9 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Walleye Capital held 126,005 shares of Ascendis Pharma A/S worth $33.6M as of Q2 2026.
Walleye Capital bought 125,968 Ascendis Pharma A/S shares in Q2 2026, an estimated $29.4M.
Ascendis Pharma A/S made up 0.12% of Walleye Capital's portfolio in Q2 2026, its #118 holding.
Walleye Capital first reported a position in Ascendis Pharma A/S in Q4 2023 and has held it in 9 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.